Head of Cancer Metabolism Global Development Oncology & Immuno-Oncology
Susan Pandya is the Head of Cancer Metabolism Global Development Oncology & Immuno-Oncology at Servier Pharmaceuticals. She is a passionate and innovative oncologist with over a decade of oncology drug development experience in both academic and biotech settings.
Susan comes to Servier from Agios Pharmaceuticals, where she spent the last 5 years leading Oncology Clinical Development. Susan has worked in pivotal programs, including one with IDH1 mutant cholangiocarcinoma, which resulted in submitting a supplemental new drug application for ivosidenib. Earlier in her career, she led the development of early-stage oncology and muscle disease assets at Acceleorn Pharma.
Susan earned her Doctor of Medicine from Tufts University School of Medicine and completed her residency in internal medicine and fellowship in Hematology/Oncology at the Beth Israel Deaconess Medical Center (BIDMC), a Harvard University teaching hospital. She continued her career as a board certified Hematologist/Oncologist at BIDMC with a focus on early phase clinical development as the Associate Director of the Phase 1 experimental therapeutics program, while maintaining a clinical practice in GI and Breast Oncology where she mentored medical students, residents and fellows in training.
To learn more about Susan connect with her on LinkedIn.
More from Servier
Servier Pharmaceuticals is a privately held pharmaceutical company focused on oncology. Everything we do is to bring the promise of tomorrow to the patients we serve.Learn More
Servier Pharmaceuticals is an independent, privately held United States company launched by Servier Group, a unique global organization, and is governed by a non-profit foundation.Learn More
Servier has a 65-year history of helping provide innovative medicines to patients globally. In the United States, Servier intends to uphold and build upon that history.Learn More